DOD awards UC Irvine $8M to develop Q fever vaccine

UC Irvine

While Coxiella burnetii, the bacterium that causes Q fever, is rarely fatal in humans, it has been aerosolized for use as a biological weapon before. A University of California, Irvine, team won $8 million from the DOD's Defense Threat Reduction Agency to develop a new vaccine against the bacterium.

The team will use the funds to identify antigens that provoke an immune response against Coxiella burnetii and to develop synthetic agents that can augment and control the immune response, the university said in a statement Monday. This approach could potentially be used to develop vaccines against other infectious diseases, said Philip Felgner director of the protein microarray laboratory, infectious disease at UC Irvine's School of Medicine.

Once the antigen targets are identified, the UC Irvine team will collaborate with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) on animal studies.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

According to the CDC, a Q fever vaccine has been developed in Australia and used successfully to protect people in occupational settings. It is not available in the U.S. Besides, despite its effectiveness, the vaccine has severe side effects that restricts its widespread use, Felgner said in the statement.

The program is an offshoot of a research hub dedicated to fighting bioterrorism threats and infectious diseases, which UC Irvine set up in 2005 with a $40 million grant from the NIAID. Meanwhile, Providence, RI-based EpiVax scooped up $5.2 million from the DOD last year to develop a new vaccine for Q fever.

- here's the statement


Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.